

mit



Eur päisches  
Patentamt

European  
Patent Office

PCT/EP

99/07376

Office européen  
des brevets

REC'D 09 NOV 1999

WIPO PCT

09/786880

EP 99/7376

Bescheinigung Certificate

Attestation

Die angehefteten Unterla-  
gen stimmen mit der  
ursprünglich eingereichten  
Fassung der auf dem näch-  
sten Blatt bezeichneten  
europäischen Patentanmel-  
dung überein.

The attached documents  
are exact copies of the  
European patent application  
described on the following  
page, as originally filed.

Les documents fixés à  
cette attestation sont  
conformes à la version  
initialement déposée de  
la demande de brevet  
européen spécifiée à la  
page suivante.

Patentanmeldung Nr. Patent application No. Demande de brevet n°

98402255.8

## PRIORITY DOCUMENT

SUBMITTED OR TRANSMITTED IN  
COMPLIANCE WITH RULE 17.1(a) OR (b)

Der Präsident des Europäischen Patentamts:  
Im Auftrag

For the President of the European Patent Office

Le Président de l'Office européen des brevets  
p.o.

I.L.C. HATTEN-HECKMAN

DEN HAAG, DEN  
THE HAGUE, 03/11/99  
LA HAYE, LE

00000000

**THIS PAGE BLANK (USPTO)**



Europäisches  
Patentamt

European  
Patent Office

Office européen  
des brevets

**Blatt 2 der Bescheinigung  
Sheet 2 of the certificate  
Page 2 de l'attestation**

Anmeldung Nr.:  
Application no.: 98402255.8  
Demande n°:

Anmeldetag:  
Date of filing: 11/09/98  
Date de dépôt:

Anmelder:  
Applicant(s):  
Demandeur(s):  
HOECHST MARION ROUSSEL  
92800 Puteaux  
FRANCE

Bezeichnung der Erfindung:  
Title of the invention:  
Titre de l'invention:

Method for screening antimycotic substances using essential genes from *C. albicans*, and said genes

In Anspruch genommene Priorität(en) / Priority(ies) claimed / Priorité(s) revendiquée(s)

Staat:  
State:  
Pays:

Tag:  
Date:  
Date:

Aktenzeichen:  
File no.  
Numéro de dépôt:

Internationale Patentklassifikation:  
International Patent classification:  
Classification internationale des brevets:

C12Q1/68, C12Q1/18

Am Anmeldetag benannte Vertragsstaaten:  
Contracting states designated at date of filing: AT/BE/CH/CY/DE/DK/ES/FI/FR/GB/GR/IE/IT/LI/LU/MC/NL/PT/SE  
Etats contractants désignés lors du dépôt:

Bemerkungen:  
Remarks:  
Remarques:

**THIS PAGE BLANK (USPTO)**

**THIS PAGE BLANK (USPTO)**

---

17. 09. 1998

1

METHOD FOR SCREENING ANTIMYCOTIC SUBSTANCES USING  
ESSENTIAL GENES FROM C. ALBICANS, AND SAID GENES

The present invention relates to a method for  
5 screening for antimycotic substances in which essential  
genes from mycetes, particularly from Candida albicans  
(C.albicans) as well as functionally similar genes from  
other pathogenic mycetes, or the corresponding encoded  
proteins, are used as targets. The invention also relates  
10 to specific C. albicans genes.

The spectrum of known fungal infections stretches  
from fungal attack of skin or nails to potentially  
hazardous mycotic infections of the inner organs; Such  
infections and resulting diseases are known as mycosis.

15 Antimycotic substances (fungistatic or fungicidal)  
are used for treatment of mycosis. However, up to now,  
relatively few substances with pharmacological effects are  
known, such as Amphotericin B, Nystatin, Pimaricin,  
Griseofulvin, Clotrimazole, 5-fluoro-cytosine and  
20 Batraphene. The drug treatment of fungal infections is  
extremely difficult, in particular because both the host  
cells and the mycetes, are eucaryotic cells. Administration  
of drugs based on known antimycotic substances results  
therefore often in undesired side-effects, for example  
25 Amphotericin B has a nephrotoxic effect. Therefore, there  
is a strong need for pharmacologically efficient substances  
usable for the preparation of drugs, which are suitable for  
prophylactic treatments of immunodepressive states or for  
the treatment of an existing fungal infection. Furthermore,  
30 the substances should exhibit a specific spectrum of action  
in order to selectively inhibit the growth and  
proliferation of mycetes without affecting the treated host  
organism.

The aim of the present invention is to provide a  
35 method for the identification of antimycotic substances and  
especially for the identification of anti-Candida  
substances. An essential feature of this method is that

essential genes from mycetes are used as targets for the screening.

The present invention thus concerns a method for screening antimycotic substances wherein an essential gene  
5 from mycetes or a functionally similar gene in another pathogenic mycete, or the corresponding encoded protein, is used as target and wherein the essential gene is selected from the group consisting of CaNL256, CaBR102 and CaIR012.

According to one embodiment of the method of the  
10 invention mycete cells which express the essential gene, or a functionally similar mycete gene, to a different level are incubated with the substance to be tested and the growth inhibiting effect of the substance is determined.

15 According to another embodiment, said target gene or the corresponding target gene encoded protein is contacted in vitro with the substance to be tested and the effect of the substance on the target is determined.

According to another embodiment, the screened  
20 substances inhibit partially or totally the functional expression of the essential genes or the functional activity of the encoded proteins.

According to one embodiment the screened substances  
25 partially or totally inhibit the activity of dihydropteroate synthase (DHPS) and/or 7,8-dihydro-6-hydroxymethylpterin-pyrophosphokinase (HPPK).

According to another embodiment, the mycete species are selected from the group comprising Basidiomycetes, Ascomycetes and Hyphomycetes.

~~30 According to another embodiment of the method of the invention said functional similar genes are essential genes from Candida Spp., preferably Candida albicans, or from Aspergillus Spp., preferably from Aspergillus fumigatus.~~

35 According to another aspect, the present invention concerns a gene having the sequence of CaNL256, CaBR102 or CaIR012, identified as SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, respectively, or a functionally similar gene or a functional fragment thereof.

According to this embodiment, the functionally similar gene has a sequence identity, at the nucleotide level, with CaNL256, CaBR102 or CaIR012, respectively, of at least 50%, preferably of at least 60%, and most preferably of at least 70%.

According to another embodiment, the functionally similar gene has a sequence identity, at the amino-acid level, with CaNL256, CaBR102 or CaIR012, respectively, encoded protein(s) of at least 40%, preferably of at least 50%, more preferably of at least 60% and most preferably of at least 70%.

According to another aspect, the present invention covers the protein(s) encoded by the CaNL256, CaBR102 or CaIR012, respectively, gene(s) or a functional polypeptidic fragment thereof.

According to another aspect, the present invention provides a plasmid containing the CaNL256, CaBR102 or CaIR012, respectively, gene(s), a functionally similar gene or a functional fragment thereof

According to another aspect, the present invention provides a plasmid (bacteria containing same) deposited at the CNCM (Institut Pasteur, Paris) with the accession numbers I-2065, I-2063 and I-2064, corresponding to the CaNL256, CaBR102 and CaIR012 genes, respectively.

According to another aspect, the present invention provides a kit for diagnosis of fungal infections comprising a gene selected from the group consisting of CaNL256, CaBR102 and CaIR012, a functionally similar gene thereof, a functional fragment thereof, the corresponding encoded protein or a functional polypeptide fragment thereof.

According to another aspect, the present invention provides an antibody directed against the protein encoded by the CaNL256, CaBR102 or CaIR012, respectively, gene(s) or a polypeptide fragment thereof.

According to the invention, it is thus necessary first of all to identify said essential genes and starting from these thus identified genes, essential genes from other pathogenic mycetes can be identified. For practical

purposes, essential genes from *S. cerevisiae* are first identified and starting from them, essential genes from other pathogenic fungus, especially from *Candida*, are obtained.

5           The present invention thus discloses the identification of three essential genes from *C.albicans* and their use in a method for the screening of antimycotic substances, especially anti-*Candida* substances.

10           In order to identify essential genes of *S.cerevisiae*, individual genomic genes are eliminated through homologous recombination. If the DNA segment thus eliminated concerns an essential gene, then the deletion is lethal for the *S.cerevisiae* cells in haploid form.

15           A method, wherein the studied *S.cerevisiae* gene is replaced by a marker gene can be used to generate the corresponding genomic deletion of *S.cerevisiae* and to determine the *S.cerevisiae* cells containing the deletion.

20           As a selection marker a dominant selection marker (e.g. kanamycin resistance gene) or an auxotrophic marker can for example be used. As an auxotrophic marker, it is possible to use genes coding for key enzymes of amino acid or nucleic base synthesis. For example, one can use as a selection marker the following genes from *S.cerevisiae* :  
25           gene encoding for the metabolic pathway of leucine (e.g.LEU2-gene), histidine (e.g. HIS3-gene) or tryptophan (e.g. TRP-1 gene) or for the nucleic base metabolism of uracil (e.g. URA3-gene).

30           Auxotrophic *S.cerevisiae* strains can be used. These auxotrophic strains can only grow on nutritive media containing the corresponding amino acids or nucleotide bases. All laboratory *S.cerevisiae* strains, containing auxotrophic markers can for instance be used. When diploid *S.cerevisiae* strains are used, then the corresponding marker gene must be homozygously mutated. Strain CEN.PK2  
35           or isogenic derivatives thereof can be used.

          Strains containing no suitable auxotrophic marker can also be used such as prototrophic *S.cerevisiae* strains. Then a dominant selection marker e.g. resistance gene, such



as kanamycin resistance gene can be used. A loxP-KanMX-loxP cassette can advantageously be used for this purpose.

For the homologous recombination replacing the whole DNA sequence or part thereof of a *S.cerevisiae* gene, DNA fragments are used wherein the marker gene is flanked at the 5'- and 3'-ends by sequences which are homologous to the 5'- and 3'-ends of the studied *S.cerevisiae* gene.

Different processes can be used for the preparation of the corresponding DNA fragments which are also appropriate for the deletion of any specific *S.cerevisiae* gene. A linear DNA-fragment is used for the transformation of the suitable *S.cerevisiae* strain. This fragment is integrated into the *S.cerevisiae* genome by homologous recombination. These processes include:

1. "Conventional method" for the preparation of deletion cassettes (Rothstein, R.J. (1983) Methods in Enzymology, Vol. 101, 202-211).

2. "Conventional Method" using the PCR technique ("modified conventional method").

3. SFH (short flanking homology)- PCR method (Wach, A. et al. (1994) Yeast 10: 1793-1808; Gültner, U. et al. (1996) Nucleic Acids Research 24:2519-2524).

1. In the "conventional method" for the preparation of deletion cassettes in the *S.cerevisiae* genome, the gene to be studied is either already present in an appropriate vector or is integrated in such a vector. With this method, any pBR- pUC- and pBluescript®-derivates can be used for example. A major part of the target gene sequence is eliminated from the vector, for instance using appropriate

---

restriction sites, conserving however the 3'- and 5'- regions of the studied gene inside the vector. The selected marker gene is integrated between the remaining regions.

2. In the modified form of this "conventional method", PCR is used. This method allows amplification of the 3'- and 5'-terminal regions of the coding sequence of the studied *S.cerevisiae* gene. This method amplifies selectively both terminal regions of the studied gene, therefore, two PCR-reactions must be carried out for each studied gene, amplifying once the 5'-end, and once the 3'-

end of the gene. The length of the amplified terminal DNA-fragment depends on the existing restriction sites. The amplified terminal ends of the studied gene have generally a length of 50 to 5000 base pairs (bp), preferably a length  
5 between 500 and 1000 bp.

As template for the PCR-reactions, genomic DNA of *S.cerevisiae* or wild-type genes can be used. The primer-pairs (a sense and an antisense primer, respectively) are constructed so that they correspond to the 3'-end and the  
10 5'-end sequence of the studied *S.cerevisiae* gene. Especially, the primer is selected such as to allow its integration by way of appropriate restriction sites.

As vectors, pBR- pUC- and pBluescript®-derivates can be used. In particular vectors already containing a  
15 gene encoding the selection marker, are appropriate. In particular, vectors can be used, which contain genes of the selection marker HIS3, LEU2, TRP1 or URA3.

The DNA segments of the studied *S.cerevisiae* gene, obtained by PCR, are integrated in the vector at both sides  
20 of the selection marker, so that subsequently, as in the "conventional method", the selection marker is flanked on both ends by DNA sequences which are homologous to the studied gene.

3. Homologous recombination in *S.cerevisiae* takes  
25 place in a very efficient and precise manner and the length of the DNA sequence homologous to the studied *S.cerevisiae* gene flanking the selection marker gene can in fact be considerably shorter than with the "modified conventional method". The flanking ends homologous to the studied  
30 ~~*S.cerevisiae* gene need to present a length of only about~~  
20-60 bp, preferably 30-45 bp. The SFH-PCR method is particularly advantageous as the laborious cloning step can be obviated.

A PCR reaction is carried out on a DNA-template  
35 containing the gene for the selection marker to be used, wherein the primers are constructed so that the DNA sequence of the sense primer is homologous to the 5'-end of the selection marker sequence and so that the primer presents in addition at its 5'-end a region of preferably

40 nucleotides, which corresponds to the 5'-terminal sequence of the studied *S.cerevisiae* gene. The antisense primer is constructed in an analogous manner, i.e. it is complementary to the 3'-end of the gene sequence of the selection marker, wherein this primer contains at its 5'-end a region of also preferably 40 nucleotides, which corresponds to the complementary strand of the 3'-terminal coding sequence of the studied gene.

For the amplification of *S.cerevisiae* genes to be studied by the SFH-PCR method, vectors containing the gene for the auxotrophic marker or selection marker can be used. Especially, plasmid pUG6 is used as the template. This plasmid contains a loxP-KanMX-loxP cassette (Gültner, U. et al. (1996) *Nucleic Acids Research* 24: 2519-2524). In other terms, the Kanamycin resistance gene is flanked at both ends by a loxP sequence (loxP-KanMX-loxP cassette). This cassette is advantageous in that the Kanamycin resistance gene can be eventually eliminated from the *S.cerevisiae* genome after integration of the loxP-KanMX-loxP cassette into the *S.cerevisiae* gene to be studied. Cre-recombinase of bacteriophage P1 can be used for this purpose. Cre-recombinase recognizes the loxP sequences and induces elimination of the DNA located between the two loxP sequences by a homologous recombination process. As a result only one loxP sequence remains and the so-called marker regeneration occurs, i.e. the *S.cerevisiae* strain may be transformed again using the loxP-KanMX-loxP cassette. This is particularly advantageous, when at least two functionally similar genes are to be deleted in order to obtain a lethal phenotype.

With the PCR-method, the PCR reaction primers are at the 3'-end a preferably 20 nucleotide long sequence, which is homologous to the sequence situated left and/or right of the loxP-KanMX-loxP cassette, and at the 5'-end a preferably 40 nucleotide long sequence, which is homologous to the terminal ends of the gene to be studied.

Using the three methods, one obtains linear deletion cassettes containing the gene encoding the selection marker, which is flanked on both sides by

homologous sequences of the gene to be studied. The deletion cassettes are used for the transformation of diploid *S.cerevisiae* strains. The diploid strain *S.cerevisiae* CEN.PK2 (Scientific Research & Development GmbH, Oberursel) can be used for example for this purpose. [CEN.PK2 Mata/MAT  $\alpha$  ura3-52/ura3-52 leu2-3, 112/leu2-3, 112his3 $\Delta$ 1/his3 $\Delta$ 1 trp1-289/trp1-289 MAL2-8<sup>C</sup>/MAL2-8<sup>C</sup> SUC2/SUC2]

The strain CEN.PK2 is prepared and cultivated using known methods (Gietz, R.D. et al. (1992) Nucleic Acids Research 8: 1425; Güldener, U. et al. (1996) Nucleic Acids Research 24:2519-2524).

The cells of the *S.cerevisiae* strain used are transformed according to known processes with an appropriate DNA quantity of the linear deletion cassette (e.g. Sambrook et al. 1989). Thereafter, the medium in which the cells are cultivated is replaced by a new medium, a so-called selective medium, which does not contain the corresponding amino acid (e. g. histidine, leucine or tryptophan) or nucleic base (e. g. uracil) or, when using a deletion cassette containing the kanamycin resistance gene, by a medium containing geneticin (G418<sup>®</sup>) (e.g. a complete medium (YEPA) containing geneticin). Alternatively, the transformed cells may be plated on agar plates prepared using the corresponding media. Thereby, one selects the transformed cells, in which a homologous recombination occurred, since only those cells can grow under these modified conditions.

~~However, in most cases, only one of the two copies~~  
of the gene in the double chromosome set of a diploid *S.cerevisiae* strain is replaced by the DNA of the deletion cassette during the transformation, resulting in a heterozygote-diploid *S.cerevisiae* mutant strain, wherein one copy of the gene studied is replaced by a selection marker, while the other copy of the gene is maintained in the genome. This presents the advantage that in case of a deletion of an essential gene, due to the existence of the

second copy of the essential gene, the mutant *S.cerevisiae* strain is still viable.

The proper integration of the deletion cassette DNA at the predetermined chromosomal gene locus (gene locus of the gene to be studied) may be checked by Southern-Blot Analysis (Southern, E.M. (1975) *J. Mol. Biol.* 98:503-517) or by diagnostic PCR analysis using specific primers (Güldener, U. et al. (1996) *Nucleic Acids Research* 24:2519-2524)

The genetic separation of individual diploid cells may be monitored by tetrad analysis. To this end, reduction division (meiosis) is induced in the diploid cells, especially heterozygote mutant strains, using known methods such as nitrogen impoverishment on potassium acetate plates (Sherman, F. et al. (1986) Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N. Y.; Guthrie, C. and Fink, G.R. (1991) *Methods in Enzymology*, Vol 194. Academic Press, San Diego, 3-21; Ausubel, F. M. et al. (1987) *Current Protocol in Molecular Biology* John Wiley and Sons, Inc., Chapter 13). Meiosis results only in asci with four ascospores (segregated), which can be individualized after partial enzymatic digestion of the ascospore wall with zymolyase (Ausubel et al. (1987)) by way of micromanipulators (e.g. SINGER). For example when a tetrad analysis is carried out on a heterozygote-diploid mutant strain in which an essential gene present in the double chromosome set is replaced on one chromosome by homologous recombination, then only two segregated ascospores are viable, namely those which carry the essential gene. The two remaining segregated ascospores are not viable because they lack the essential gene.

In order to check if the genes studied by this method are really essential or if the homologous recombination leads to an alteration of an essential gene adjacent to the gene locus of the gene studied, the heterozygote diploid *S.cerevisiae* mutant strain is transformed with a centromere plasmid containing said studied gene.

A tetrad analysis is carried out on the transformants. When four instead of two viable segregates are obtained, then the studied gene contained in the centromere plasmid can complement the defect of the two non-viable haploid *S.cerevisiae* cells/mutant strains, which demonstrates that the studied *S.cerevisiae* gene is essential.

Preferably, plasmids present in low copy number, e.g. one or two copies per cell are used as centromere plasmids. For example plasmids pRS313, pRS314, pRS315 and pRS316 (Sijkorski, R. S. and Hieter, P. (1989) Genetics 122: 19-27) or similar plasmids can be used for this purpose. Preferably, the studied genes are integrated in said plasmids including their 3'- and 5'-end non-coding regions.

Individual *S.cerevisiae* genes may be studied using the above-described method, their sequences being totally or partially known. The complete genomic sequence of *S.cerevisiae* was made accessible to the public via the WWW (World Wide Web) on April 24, 1996.

Different possibilities exist to have access to the *S.cerevisiae* genomic DNA sequence via the WWW.

MIPS (Munich information Centre of Protein Sequence) Address <http://speedy.mips.biochem.mpg.de/mips/yeast/>

SGD (Saccharomyces Genome Database, Stanford)  
Address <http://genome-www.stanford.edu/Saccharomyces>  
YPD (Yeast Protein Database, Cold Spring Harbor)  
Address <http://www.proteome.com/YPDhome.html>

The complete *S.cerevisiae* DNA sequence is also accessible via FTP (file transfer protocol) in Europe (e.g. at the address: <ftp.mips.embnet.org>) in the U.S.A. (address: <genome-ftp.stanford.edu>) or in Japan (address: <ftp.nig.ac.jp>).

3 essential genomic *S.cerevisiae* genes have been identified by this way, YNL256w, YBR102c and YIR012w.

The essential genes of *S.cerevisiae* are then used to identify corresponding functionally similar genes in other mycetes.

By functionally similar genes in other mycete species, is meant genes which have a function similar or identical to that of the identified essential genes of *S.cerevisiae*. Functionally similar genes in other mycetes may, but need not be homologous in sequence to the corresponding essential *S.cerevisiae* genes. Functionally similar genes in other mycetes may exhibit only moderate sequence homology at the nucleotide level to the corresponding essential *S.cerevisiae* genes. By moderate sequence homology it is meant in the present invention genes having a sequence identity, at the nucleotide level, of at least 50%, more preferably of at least 60% and most preferably of at least 70%.

In addition, functionally similar genes in other mycetes may, but need not encode proteins homologous in sequence to the proteins encoded by the essential *S.cerevisiae* genes. Functionally similar proteins in other mycetes may exhibit moderate protein sequence homology to the proteins encoded by the essential *S.cerevisiae* genes.

By moderate protein sequence homology is meant in the present invention proteins having a sequence identity, at the amino-acid level, of at least 40%, preferably of at least 50%, more preferably of at least 60% and most preferably of at least 70%.

Genes homologous in sequence may be isolated according to known methods, for example via homologous screening (Sambrook, J. et al. (1989) Molecular Cloning Cold Spring Harbor Laboratory Press, N.Y.) or via the PCR technique using specific primers from genomic libraries and/or cDNA libraries of the corresponding mycetes.

According to one embodiment, genes homologous in sequences are isolated from cDNA libraries. In order to find out functionally similar genes in other mycetes, mRNA is isolated from mycete species to be studied according to known methods (Sambrook et al. 1989) and cDNA is synthesized according to known methods (Sambrook et al. 1989; or cDNA synthesis kits, e.g. from STRATAGENE).

The prepared cDNA is directionally integrated in a suitable expression vector.

For example, synthesis of the first cDNA strand may be carried out in the presence of primers having appropriate restriction sites in order to allow a subsequent cloning in the proper orientation with respect to the expression vector promoter. As restriction sites, any known restriction site may be used. As a primer, for instance the following primer, 50 nucleotides long may be used:

5'-GAGAGAGAGAGAGAGAGAGAGAACTAGTXXXXXXTTTTTTTTTTTTTTTTTTT-3'

10           The sequence (X)<sub>6</sub> represents an appropriate restriction site, for example for XhoI.

After two-strand synthesis, the cohesive ends of the double stranded cDNA are filled (blunt end) and the cDNA ends are then ligated using a suitable DNA adaptor sequence. The DNA adaptor sequence should contain a restriction site which should be different from the restriction site used in the primer for the synthesis of the first cDNA strand. The DNA adaptor may comprise for example complementary 9- or 13-mer oligonucleotides, whose ends represent the cohesive end of a restriction site. These ends may be for example a EcoRI-site:

5'           XXXXXGGCACGAG 3'

3'           XCCGTGCTC 5'

25           The single-stranded X in the adaptor sequence represent the cohesive end of a restriction site.

The cDNA provided with corresponding adaptor sequences is then cleaved using restriction endonuclease, whose recognition site was used in the primer for the synthesis of the first cDNA strand, for example XhoI. The cDNA thus obtained would have according to this example 3'-XhoI and 5'-EcoRI protruding ends and could be therefore directionally integrated into an expression vector cleaved with XhoI and EcoRI.

As expression vectors, among others, E. coli/S.cerevisiae shuttle vectors, i.e. vectors usable in E. coli as well as in S.cerevisiae are suitable. Such vectors may then be amplified for instance in E. coli. As expression vectors, those which are present in a high copy number as well as those present in a low copy number in



S.cerevisiae cells can be used. For this purpose, for example vectors selected in the group consisting of pRS423 - pRS426 (pRS423, pRS424, pRS425, pRS426) and/or pRS313-pRS316 (pRS313, pRS314, pRS315, pRS316) (Sikorki, R.S. and  
5 Hieter, P. (1989) Genetics 122: 19-27; Christianson T. W. et al. (1992) Gene 110: 119-122) are suitable.

Expression vectors should contain appropriate S.cerevisiae promoters and terminators. In case they do not have these elements, the corresponding promoters and  
10 terminators are inserted in such a way that a subsequent incorporation of the generated cDNA remains possible. Particularly suitable are the promoters of S.cerevisiae genes MET25, PGK1, TPI1, TDH3, ADHI, URA3. One may use promoters of the wild-type gene in non modified form as  
15 well as promoters which were modified in such a way that certain activator sequences and/or repressor sequences were eliminated. As terminators, for example the terminators of the S.cerevisiae genes MET25, PGK1, TPI1, TDH3, ADHI, URA3 are suitable.

20 According to another embodiment, genes homologous in sequence are isolated from genomic libraries. Genomic DNA libraries from mycetes can be prepared according to procedures known (for example as described in Current Protocols in Molecular Biology, John Wiley and Sons, Inc).  
25 For example, genomic DNA from mycetes can be prepared using known methods for yeast cell lysis and isolation of genomic DNA (for example commercially available kits from Bio101, Inc). The genomic DNA can be partially digested using a restriction enzyme such as Sau3AI and the fragments are  
30 size selected by agarose gel electrophoresis. DNA fragments having for example a size of 5-10kb are then purified by classical methods (as for example, using Gene Clean kit from Bio101) and inserted in a E.coli/yeast shuttle vector such as YEP24 (described e.g. by Sanglard D., Kuchler K.,  
35 Ischer F., Pagani J-L., Monod M. and Bille J., Antimicrobial Agents and Chemotherapy, (1995) Vol.39 No11, P2378-2386) cut by a restriction enzyme giving compatible ends (for example BamHI for Sau3AI-cut genomic DNA). The resulting expression library can be amplified in E.coli.

However any known method, appropriate for the preparation of a genomic library, can be used in the present invention.

In order to find the genes in the studied mycete species, which are functionally similar to essential genes of *S.cerevisiae*, one *S.cerevisiae* essential gene is placed under control of a regulated promoter, either as an integrative (1) or extrachromosomal (2) gene.

1. For the integration of a regulated promoter in the *S.cerevisiae* genome, one replaces the native promoter of the selected essential gene by the regulated promoter, for example by homologous recombination via PCR (Güldener et al. (1996). The homologous recombination via PCR can be carried out for example in the diploid *S.cerevisiae* strain CEN.PK2. The successful integration into one chromosome can be checked in haploid cells following tetrad analysis.

Using the tetrad analysis, one obtains four viable ascospores, wherein in two haploid segregates, the selected essential gene is placed under the control of the native promoter, while the essential gene in the two remaining segregates is placed under the control of the regulated promoter.

The last mentioned haploid segregates are used for the transformation with the cDNA or the genomic DNA present in the recombinant vector.

2. Using the extrachromosomal variant, the selected essential *S.cerevisiae* gene is first inserted in a suitable expression vector, for example a *E.coli/S.cerevisiae* shuttle vector. For this purpose, the essential gene may be amplified via PCR from genomic *S.cerevisiae* DNA starting from the ATG initiation codon up to and including the termination codon. The primers used for this purpose may be constructed in such a way that they contain recognition sites for appropriate restriction enzymes, facilitating a subsequent insertion under control of a regulated promoter in an expression vector.

The recombinant expression vector with the plasmid copy of the essential *S.cerevisiae* gene under the control of a regulated promoter is subsequently used for the

transcomplementation of the corresponding mutant allele. The corresponding mutant allele may be selected from the heterozygote-diploid mutant strains prepared by eliminating, partially or totally, by homologous recombination an essential mycete gene listed above and as described above.

The expression vector with the selected essential *S.cerevisiae* gene is transformed in the corresponding heterozygote-diploid mutant strain carrying instead of the selected essential *S.cerevisiae* gene, a selection marker gene. The transformants are isolated by selection based on the auxotrophic marker contained in the expression vector used. The thus transformed heterozygote-diploid mutant strains are submitted to a tetrad analysis. One obtains four viable segregates. By retracing the corresponding markers of the mutant allele and the expression vector, the transformed wild-type segregates may be distinguished from segregates which do not contain the genomic copy of the essential gene. Segregates, which do not contain the genomic copy of the selected essential gene, are designated as trans-complemented haploid mutant strains. They are subsequently used for transformation with cDNA or genomic DNA libraries from other mycete species present in appropriate vectors.

As regulated promoters, inducible or repressible promoters may be used. These promoters can consist of naturally and/or artificially disposed promoter sequences.

As regulated promoters, for example the promoters of *GAL1* gene and the corresponding promoter derivatives, such as for example promoters, whose different *UAS* (upstream activation sequence) elements have been eliminated (*GALS*, *GALL*; Mumberg, J. et al. (1994) *Nucleic Acids Research* 22:5767-5768) may be used. As regulated promoters, promoters of gluconeogenic genes may also be used, such as e.g. *FBP1*, *PCK1*, *ICL1* or parts therefrom, such as e.g. their activation sequence (*UAS1* and/or *UAS2*) or repression sequence (*URS*, upstream repression sequence) (Niederacher et al. (1992), *Curr. Genet.* 22: 636-670; Proft et al. (1995) *Mol. Gen. Gent.* 246: 367-373; Schüller et al.

(1992) EMBO J; 11: 107-114; Guarente et al. (1984) Cell 36: 503-511).

A *S.cerevisiae* mutant strain modified in this manner can be cultivated under growth conditions, in which  
5 the regulated promoter is active, so that the essential *S.cerevisiae* gene is expressed. The *S.cerevisiae* cells are then transformed with a representative quantity of the library containing the studied mycete species cDNA or genomic DNA. Transformants express additionally the protein  
10 whose coding sequence is present in the recombinant vector.

The method contemplates that the growth conditions may be modified in such a way as to inhibit the regulated promoter, under the control of which is the selected essential gene. Especially, growth conditions may be  
15 changed by replacing the growth medium. When for example the GAL1 promoter or a derivate thereof is used, one can replace the galactose-containing medium (induced state) by a glucose-containing medium (repressed state).

These modified conditions are lethal for the  
20 *S.cerevisiae* cells in which the recombinant vector does not carry the functionally similar genomic DNA or cDNA of the studied mycete species. On the contrary, the *S.cerevisiae* cells in which the recombinant vector expresses a functionally similar coding sequence of the studied mycete  
25 species, are viable, since in these cells the lethal metabolic defect is complemented by the protein encoded by the functionally similar gene.

The method contemplates that the recombinant vector (the plasmid) is isolated from the surviving transformants  
30 using known method (Strathern, J.N. and Higgins, D.R. (1991). Plasmids are recovered from yeast into *Escherichia coli* shuttle vectors in: Guthrie, C. and Fink, G.R. Methods in Enzymology, Volume 194. Guide to yeast genetic and molecular Biology. Academic Press, San Diego, 319-329) and  
35 the cDNA or genomic DNA is analyzed using DNA-analysis methods such as DNA sequencing. (Sanger et al. (1977), Proc. Natl. Acad. Sci. USA 74: 5463-5467)

Essential *S.cerevisiae* genes may thus be used for the identification of functionally similar genes and/or

genes homologous in sequence in other mycetes, especially essential genes functionally similar and/or homologous in sequence in mycetes pathogenic to human, animal and plants. For this purpose for example mycetes of the classes

5 phycomycetes or eumycetes may be used, in particular the subclasses basidiomycetes, ascomycetes, especially mehiiascomycetales (yeast) and plectascales (mould fungus) and gymnascales (skin and hair fungus) or of the class of hyphomycetes, in particular the subclasses conidiosporales

10 (skin fungus) and thallosporales (budding or gemmiparous fungus), among which particularly the species mucor, rhizopus, coccidioides, paracoccidioides (blastomyces brasiliensis), endomyces (blastomyces), aspergillus, penicilium (scopulariopsis), trichophyton (ctenomyces),

15 epidermophton, microsporon, piedraia, hormodendron, phialophora, sporotrichon, cryptococcus, candida, geotrichum and trichosporon.

Of particular interest is the use of Candida Spp. especially Candida albicans, Candida glabrata, Aspergillus

20 Spp., especially Aspergillus fumigatus, Coccidioides immitis, Cryptococcus neoformans, Histoplasma capsulatum, Blastomyces dermatitidis, Paracoccidioides brasiliens and Sporothrix schenckii.

Starting from the genes of S.cerevisiae, identified

25 according to the above-described method, Applicants cloned corresponding essential genes from C.albicans i.e. CaNL256, CaYBR102 and CaIR012 by the following method.

First, oligonucleotide(s) is(are) selected in the sequence of the S.cerevisiae gene or a homologous C.

30 ~~albicans sequence in order to amplify the corresponding~~ fragment of C.albicans. After cloning, the obtained fragment (exhibiting a sequence of about several hundred bp) is used as a probe for screening a C.albicans (genomic) DNA library. The screening may include the following

35 steps: clones were spread on dishes, covered with filters where the DNA was crosslinked to the filters, filters are hybridized, the positive colonies are then detected. The selected clone(s) is (are) then sequenced.

The method contemplates that essential mycete genes are used to identify substances which may inhibit partially or totally the functional expression of these essential genes and/or the functional activity of the encoded proteins. Substances may be identified in this fashion, which inhibit mycetes growth and which can be used as antimycotics, for example in the preparation of drugs.

The present invention especially covers a method for screening such inhibiting substances wherein an essential gene from *C.albicans* selected from CaNL256, CaBR102 and CaIR012, or a functionally similar gene in another pathogenic mycete or the corresponding encoded protein is used as target.

By functionally similar genes in other pathogenic mycete species, is meant genes which have a function similar or identical to that of the identified essential genes of *C.albicans*. Functionally similar genes in other pathogenic mycetes may, but need not be homologous in sequence to the corresponding essential *C.albicans* genes. Functionally similar genes in other pathogenic mycetes may exhibit only moderate sequence homology at the nucleotide level to the corresponding essential *C.albicans* genes. By moderate sequence homology it is meant in the present invention genes having a sequence identity, at the nucleotide level, of at least 50%, more preferably of at least 60% and most preferably of at least 70%.

In addition, functionally similar genes in other pathogenic mycetes may, but need not encode proteins homologous in sequence to the proteins encoded by the essential *C.albicans* genes. Functionally similar proteins in other mycetes may exhibit moderate protein sequence homology to the proteins encoded by the essential *C.albicans* genes.

By moderate protein sequence homology is meant in the present invention proteins having a sequence identity, at the amino-acid level, of a least 40%, preferably of at least 50%, more preferably of at least 60% and most preferably of at least 70%.

A particular feature of this method is that essential mycete genes or the corresponding encoded proteins are used as targets for the screening of the substances. The method contemplates that essential  
5 C.albicans genes as well as functionally similar genes and/or genes homologous in sequence of other pathogenic mycetes or the corresponding encoded proteins may be used as targets.

According to one embodiment of the screening method  
10 of the invention, mycetes cells are provided, which contain the essential gene used as target, and those cells are incubated with the substance to be tested. By this way, the growth inhibitory effect of this substance with respect to the essential target gene is determined.

15 The mycetes cells which express the essential target gene to a different degree are used, and these cells are then incubated with the substance to be tested and the growth inhibitory effect of this substance is determined.

The method includes the use of two or more mycetes  
20 cells, or strains derived therefrom, which differ in that they express the essential target gene to a different degree.

For example, two, three, four, five, ten or more mycetes cells or the corresponding mycetes strains may be  
25 comparatively analysed with respect to the growth inhibitory effect of a substance used in a defined concentration. Through such expression degree series, antimycotic substances may be distinguished from cytotoxic or inactive substances.

30 A particular embodiment of the method includes the use of haploid mycetes cells/ strains for the screening, especially haploid S.cerevisiae cells/ strains.

The method contemplates the integration of the essential gene selected as a target in a suitable  
35 expression vector.

As expression vectors E.coli/S.cerevisiae shuttle vectors are for example suitable. Especially vectors differing in their copy number per cell may be used. Therefore, one may use vectors, which are present in the

transformed *S.cerevisiae* cells in a high copy number, or one can also use those with a low copy number. One embodiment comprises the use of expression vectors which allow the integration of the target gene in the *S.cerevisiae* genome.

For example the vectors pRS423, pRS424, pRS425, pRS426, pRS313, pRS314, pRS315, pRS316, pRS303, pRS304, pRS305, pRS306 (Sikorki and Hieter, 1989; Christianson et al. 1992) are appropriate as expression vectors.

The vectors of the series pRS423 - pRS426 are present in a high copy number, about 50 - 100 copies/ cell. On the contrary, the vectors of the series pRS313 - pRS316 are present in a low copy number (1 - 2 copies / cell). When expression vectors from these two series are used, then the target gene is present as an extrachromosomal copy. Using the vector of the series pRS303 - pRS306 allows the integration of the target genes into the genome. Using these three different expression vector types allows a gradual expression of the studied functionally similar essential gene.

The method includes that the growth inhibitory effect of substances with respect to mycetes cells/strains is comparatively determined using expression vectors differing for instance in the copy number of the vector/ cell.

Such cells may express the essential target gene to a different degree and may exhibit a graduated reaction with respect to the substance.

The method includes also, that a target gene expression of different strength is obtained in different mycetes cells (regulated overexpression) by insertion of the target gene in the expression vector between specific selected *S.cerevisiae* promoters and terminators. *S.cerevisiae* promoters which are constitutively expressed, but with different strength, are suitable. Examples for such promoters are native promoters of *S.cerevisiae* genes MET25, PGK1, TPI1, TDH3, ADH1, URA3, TRP1, as well as corresponding derivatives therefrom, for example promoter



derivatives without specific activator and/or repressor sequences.

Regulated promoters are also appropriate for the graduated over-expression of the target gene. The native promoters of the GAL1 genes and/or corresponding derivatives thereof, for example promoters, in which different UAS elements have been eliminated. (GALS, GALL; Mumberg et al. (1994) Nucleic Acids Research 22: 5767-5768) as well as promoters of gluconeogenic genes, for example the promoters FBP1, PCK1, ICL1, or parts thereof, for example their activator- (UAS1 or UAS2) or repressor- (URS) sequences are used in corresponding non activable and/or non repressible test promoters (Schüller et al. (1992) EMBO J. 11: 107-114) Guarente et al. (1984) Cell 36: 503-511; Niederacher et al. (1992) Curr. Genet. 22: 363-370; Proft et al. (1995) Mol. Gen. Genet. 246: 367-373).

In the expression vector terminator for example the terminator sequence of *S.cerevisiae* genes MET25, PGK1, TPI1, TDH3, ADHI, URA3 may be used.

The method includes that by the use of cleverly selected expression vector types and/or the preparation of suitable expression vectors, eventually using promoters of different strength and differently regulated promoters, a series of expression vectors may be constructed, all containing the same target gene, but differing in that they express the target gene to a different extent.

The method includes the transformation of the expression vector in haploid wild-type cells of *S.cerevisiae*. The thus obtained *S.cerevisiae* cells/strains are cultivated in liquid medium and incubated in the presence of different concentrations of the tested substance and the effect of this substance on the growth behaviour of the cells/strains expressing the target gene to a different degree is comparatively analysed. The method also includes that haploid *S.cerevisiae* cells/strains, transformed using the respective expression vector type without target gene, are used as a reference.

The method includes that the screening of the substances can be carried out in different media using

regulated promoters, especially GAL1 promoter and its derivatives (GALS and GALL), since the expression degree may be largely influenced by the choice of the respective medium. Thus, the expression degree of the GAL1 promoter  
5 decreases in the following fashion: 2 % galactose > 1 % galactose + 1 % glucose > 2 % glycerine > 2 % glucose.

The effect of the substances inhibiting the growth of wild-type cells of *S.cerevisiae*, may be partially or totally compensated by the overexpression of the  
10 functionally similar gene of another mycete species.

According to one embodiment, the method for screening antimycotic substances is carried out in vitro by contact of an essential or functionally similar gene or the corresponding encoded protein with the substance to be  
15 tested and determination of the effect of the substance on the target. Any in vitro test appropriate for determining the interaction of two molecules, such as a hybridization test or a functional test, can be used (e.g. enzymatic tests which are described in details in Bergmeyer H.U.,  
20 Methods of Enzymatic Analysis, VCH Publishers). If the screening is carried out using the encoded protein as the target, then the corresponding essential gene is inserted by any suitable method known in the art, such as PCR amplification using a set of primers containing appropriate  
25 restriction sites, (Current Protocol in Molecular Biology, John Wiley and Sons, Inc) into an expression system, such as *E. coli*, Baculovirus, or yeast, and the expressed protein is then completely or partially purified by a method known in the art. Any purification method  
30 appropriate for the purification of expressed proteins, such as affinity chromatography can be used. If the target protein function is known, a functional test can then be carried out in which the effect of the antimycotic substance on the protein function is determined. If the  
35 protein function is unknown, substances which can interact with the target protein, e.g. which bind to the encoded protein, can be tested. In such a case a test such as protection of the target protein from enzymatic digestion by appropriate enzymes can be used.

According to one specific embodiment, the method for screening antimycotic substances corresponds to an enzymatic assay wherein the activity of dihydropteroate synthase (DHPS) and/or 7,8-dihydro-6-hydroxymethylpterin-pyrophosphokinase (HPPK) is determined; the enzymatic essay can be such as disclosed in "Bergmeyer H.U., Methods in Enzymatic analysis, VCH Publishers".

Dihydropteroate synthetase (DHPS) catalyses the condensation of 6-hydroxymethyl-7,8-dihydropterin pyrophosphate to para-aminobenzoic acid to form 7,8-dihydropteroate which corresponds to the second step in the three-step pathway leading from 6-hydroxymethyl-7,8-dihydropterin to 7,8-dihydrofolate. 7,8-dihydro-6-hydroxymethylpterin-pyrophosphokinase (HPPK) catalyzes the attachment of pyrophosphate to 6-hydroxymethyl-7,8-dihydropterin to form 6-hydroxymethyl-7,8-dihydropterin pyrophosphate which corresponds to the first step in a three-step pathway leading to 7,8-dihydrofolate. All organisms require reduced folate cofactors for the synthesis of a variety of metabolites. Most microorganisms must synthesize folate de novo because they lack the active transport system of higher vertebrate cells which allows these organisms to use dietary folates. Enzymes involved in folate biosynthesis are therefore targets for a variety of antimicrobial agents. Consequently, these enzyme activities are essential to the microorganisms, and are absent in man.

The method also includes the identification of genes which are functionally similar and/or homologous in sequence to essential *C.albicans* genes from humans, animals or plants. The corresponding human, animal or plant genes may optionally be used as target genes in the method in order to test if antimycotic substances exhibit an effect on these target genes.

A particular advantage of the method is that in this way substances may be identified which efficiently inhibit mycetes growth and also the influence of these substances on corresponding functionally similar genes

and/or genes homologous in sequence to essential *C.albicans* genes from human, animal or plants may be determined.

The method includes also the possibility to check the existence of functionally similar genes and/or human, animal or plant genes homologous in sequence to the corresponding essential mycete genes, for example by checking homology of the identified essential mycete genes or parts thereof with human, animal or plant sequence genes available in data banks. In this way, it is possible to select at an early stage from the identified essential mycete genes, depending on the aim, those for which no functionally similar gene and/or no human gene homologous in sequence exist, for example.

Thereby, the method offers a plurality of possibilities to identify selectively substances with antimycotic effects, with no harmful effect on human beings.

For example, it is possible to identify substances usable for the preparation of drugs for the treatment of mycosis or prophylaxis in immunodepression states. These substances may be used for example for the manufacture of drugs usable for the treatment of mycotic infections, which occur during diseases like Aids or Diabetes. Substances which may be used for the fabrication of fungicides, especially of fungicides which are harmless for humans and animals, can also be identified.

Furthermore, the method offers the possibility to identify antimycotic substances, which selectively inhibit growth of specific mycete species only.

The screening method is particularly advantageous inasmuch as it is sufficient to know whether the genes are essential, one does not need any additional information regarding the function of the essential genes or the function of the encoded proteins. In addition, it is particularly advantageous for the identification of functionally similar genes to essential *S.cerevisiae* gene, in other mycetes where the DNA sequence is not available for many of these genes.

According to another aspect the invention provides an antibody directed against the protein encoded by the CaNL256, CaBR102 or CaIR012 gene or a polypeptidic fragment thereof. The term "antibody" encompasses monoclonal and polyclonal antibodies. Said antibodies can be prepared by method well known in the art such as those disclosed in "Antibodies, a laboratory manual", Ed. Harbow and David Lane. Cold Spring Harbor Laboratory Eds., 1988.

According to another aspect the present invention provides a kit for the diagnosis of fungal infections comprising a gene selected from the group consisting of CaNL256, CaBR102 and CaIR012, a functionally similar gene thereof, a functional fragment thereof, the corresponding encoded protein, a functional polypeptide fragment thereof or an antibody directed against the protein encoded by the CaNL256, CaBR102 or CaIR012 gene or a polypeptidic fragment thereof. Such kits can be prepared using any suitable method well known in the art.

#### Examples

##### Example 1 : CaNL256

The Internet site of Stanford (<http://candida.stanford.edu/>) gives access to preliminary sequences of the genome of *C. albicans*. One of these sequences has homology with the YNL256 gene of *S. cerevisiae*. Two oligonucleotides were selected in this sequence (5'-ATTTCATCCCATCAGTGCAGAAAG-3' and 5'-ATTGACCAATAGCTCTAATTAATG-3') in order to amplify the corresponding fragment of *C. albicans*. After cloning, we obtained a sequence of 399 bp close to the expected sequence (fig.1, SEQ ID NO:1). The deduced protein was compared with the one of YNL256, evidencing 53% similarity and 43% identity (fig.2). This fragment of 399 bp of *C. albicans* was used as a probe for screening a genomic library of *C. albicans*. The latter was prepared by partial digestion of genomic DNA of *C. albicans* by Sau3AI and cloning into the YEP24 vector at the BamHI site. The clones of the library were then spread at a density of 2000 clones per dish. Each dish was covered by a nitrocellulose filter which was then successively treated with: NaOH,

0.5M, 5 minutes; Tris, 1M, pH 7.7, 5 minutes; Tris, 0.5M, pH 7.7, NaCl, 1.25M, 5 minutes. After drying, the filters were kept for 2 hours at 80°C. Prehybridization and hybridization were carried out in a buffer of 40% formamide, 5xSSC, 20 mM Tris pH 7.7 1xDenhardt 0.1% SDS. The probe was labeled with 32P with the RediPrime kit and dCTP from Amersham UK. Hybridization took place over 17 hours at 42°C. The filters were then washed in 1x SSC, 0.1% SDS, three times for 5 minutes at room temperature and then twice for 30 minutes at 60°C, and were then submitted to autoradiography overnight. The colonies corresponding to the spots obtained were reisolated by re-spreading at low density followed by further hybridization. Three clones were thus obtained (out of 40,000), which were sequenced on an ABI 377 apparatus. The sequences were compiled using the ABI software and then analysed using the GCG software package. One of these three clones turned out to contain the complete coding sequence corresponding to the probe used; this gene was called CaNL256, whose sequence is represented Fig.3 (SEQ ID NO:2). CaNL256 has 52% of nucleotides identical to YNL256 of *S. cerevisiae*. The coding region is shorter at the N-terminus. For translation to amino acids, account was taken of the fact that, in *C. albicans*, the CTG codon is translated to Serine (there are 3 CTG codons in CaNL256). The deduced protein had 40% amino acids identical with YNL256 of *S. cerevisiae* and 41% with FAS (folic acid synthase) of *Pneumocystis carinii*. Investigation into the databases using the Blast software showed homology of two parts of the CaNL256 protein with, respectively, the bacterial enzymes Dihydropteroate Synthase (EC 2.5.1.15) (DHPS) of *Haemophilus influenzae*, *Staphylococcus haemolyticus*, *Neisseria meningitidis*, *Streptococcus pneumoniae*, *Bacillus subtilis*, *Clostridium acetobutylicum*, *Escherichia coli*, *Mycobacterium leprae* (P value less than  $e^{-28}$ ) and 7,8-dihydro-6-hydroxymethylpterin-pyrophosphokinase (EC 2.7.6.3) (HPPK) of *Bacillus subtilis*, *Escherichia coli*, *Haemophilus influenzae*, *Streptococcus pneumoniae* (P value

less than e-20). The units characteristic of DHPS and HPPK are also found in CaNL256.

Example 2 : CaBR102

The Internet site of Stanford  
5 (<http://candida.stanford.edu/>) give access to preliminary sequences of the genome of *C. albicans*. One of these sequences has homology with the YBR102 gene of *S.cerevisiae*. Two oligonucleotides were selected in this sequence (5'-AGTATTCAATTGGGTATTCC-3' and 5'-  
10 CCGGCATCATCAGTAACTCC-3') in order to amplified the corresponding fragment of *C. albicans*. After cloning, we obtained a sequence of 647 bp close to the expected sequence (fig.4, SEQ ID NO:3). The deduced protein was compared with the one of YNL102, evidencing 35% similarity and 26% identity (fig.5). This fragment was amplified using  
15 Pfu polymerase (Stratagene). The PCR product was purified (High Pure PCR Product Purification Kit, Boehringer Mannheim) and used as a probe for screening a *C. albicans* genomic DNA library. The latter was prepared by partial  
20 digestion of *C. albicans* genomic DNA with SauIIIA and cloning into the YEP-24Trp1 vector at the BamHI restriction site. 40,000 clones of the library were then spread at a density of 2000 clones per dish. Each dish was covered by a nitrocellulose filter (Membrane Hybond N<sup>+</sup>, Amersham) which  
25 was then successively treated with : 1.5 M NaCl/0.5 M NaOH, 5 minutes; 1.5 M NaCl/0.5 M Tris-HCl pH 7.2/1 mM EDTA, 3 minutes, twice; DNA was crosslinked to the filters (Amersham Life Science, ultra violet crosslinker). The probe (100 ng) was labelled with <sup>32</sup>P using the RediPrime  
30 kit and dCTP (Amersham Life Science). The filters were hybridized in a buffer containing 30% formamide, 5 x SSC, 5% Denhart's solution, 1% SDS, 100 µg /ml salmon sperm DNA and a probe concentration of 10<sup>6</sup> cpm/ml at 42°C for 16 h. The membranes were then washed three times at room  
35 temperature in 2 x SSC/0.1% SDS for 5 minutes each and three times in 1 x SSC/0.1% SDS at 60°C for 20 minutes each. the filters were then exposed overnight to an X-ray film. The colonies corresponding to the positives clones were isolated and screened a second time by the same

procedure. Two positives clones were finally obtained, which were sequenced on an ABI377 apparatus. the sequences were compiled using ABI software and then analysed using the GCG software package. The nucleotide sequences of these two clones were identical and contained the complete coding sequence corresponding to the probe used, this gene was called CaBR102, whose sequence is represented Fig.6 (SEQ ID NO:4). The translation of this nucleotide sequence was examined, account was taken of the fact that in *C. albicans* the CTG codon is translated to serine (there are 3 CTG codons in CaBR102). The deduced protein has 24% identity to *S. cerevisiae* gene YBR102.

### Example 3 : CaIR012

Chromosomal DNA from the *C. albicans* strain Caf2-1 was isolated using Yeast Cell Lysis prep Kit and Genome DNA Kit from BIO101. A 343 bp fragment from *C. albicans* genomic DNA (Fig.7, SEQ ID NO:5) was amplified with the oligonucleotide primers CaYIR012-5' (5'-GACGTCGTAGACGATACTCAAGAAG-3') and CaYIR012-3' (5'-CTGCAGTAAACCTCCAGATATAACAG-3') by PowerScript DNA polymerase (PAN Systems GmbH) using the hot start technique. The PCR product was purified from the agarose gel and labeled with fluorescein (Gene image random prime labelling module, Amersham Life Science) according to the manufacturer's instructions. Plasmid DNA from *E.coli* was isolated using Qiagen columns as recommended by the manufacturer. Screening the  $\lambda$ ZAPII *C. albicans* cDNA library was performed following the manufacturer's instructions (Stratagene Ltd.). Nylon filters (Schleicher&Schuell) were lifted from LB-plates (150 mm) with 15000 pfu/plate, denatured 5 min in 1.5M NaCl, 0.5M NaOH, neutralized 3 min in 1.5M NaCl, 0.5M Tris-HCl pH8.0, washed 3 min in 0.2 M Tris-HCl pH 7.5, 2xSSC and DNA was crosslinked to the filters (Stratagene UV crosslinker). The filters were prehybridized 4 h at 60 °C and hybridized with the fluorescein-labeled DNA probe overnight at 60 °C. Detection was performed with Anti-fluorescein AP conjugate (Signal amplification module for the FluorImager, Amersham



LIFE SCIENCE) and analysed after 20 h with a Fluorimager (Storm 860, Molecular Dynamics). Positive plaques were picked and incubated with 0.5 ml SM-buffer (100mM NaCl, 8 mM MgSO<sub>4</sub>, 50 mM Tris-HCl pH7.5, 0,01% gelatin). The  
5 selected clones were diluted, titered with host cells XL1-Blue and screened and purified a second time by the same procedure. Finally, the pBluescript SK(-) phagemid containing the DNA insert of interest was rescued by the ExAssist Helper Phage system according to the Stratagene  
10 protocol. From a total of 75000 screened plaques, 3 positive clones were identified. pBluescript SK (-) phagemid DNA was isolated, sequenced with T3 and T7 primers and the sequences were extended with custom-synthesized oligonucleotide primers. Nucleotide sequence analyses were  
15 performed with the Gene Data software package (Gene Data AG, Basel Switzerland). Similarity searches with the Swissprot database were conducted with the BLAST program (Gish, Warren and David J. States (1993). Identification of protein coding regions by database similarity search.  
20 Nat. Genet. 3:266-72.). One of these three clones turned out to contain the complete coding sequence corresponding to the probe used; this gene was called CaIR1012, whose sequence is represented Fig.8 (SEQ ID NO:6).



17. 09. 1998

## Claims:

1.-A method for the screening of antimycotic substances wherein an essential gene from mycetes or a  
5 functionally similar gene from another pathogenic mycete, or the corresponding encoded protein, is used as target and wherein the essential gene is selected from the group consisting in CaNL256, CaBR102 and CaIR012.

10 2.-The method of claim 1 wherein mycete cells which express the essential gene, or a functionally similar mycete gene, to a different level are incubated with the substance to be tested and the growth inhibiting effect of the substance is determined.

15 3.-The method of claim 1 wherein said target gene or the corresponding target encoded protein is contacted in vitro with the substance to be tested and the effect of the substance on the target is determined.

20 4.-The method according to any one of claims 1-3 wherein the screened substances partially or totally inhibit the functional expression of the essential genes or the functional activity of the encoded proteins.

25 5.-The method according to any one of claims 1-4 wherein the screened substances partially or totally inhibit the activity of dihydropteroate synthase (DHPS) and/or 7,8-dihydro-6-hydroxymethylpterin-pyrophosphokinase  
30 (HPPK) .

6.-The method according to any one of claims 1-5 wherein the mycete species are selected from the group comprising Basidiomycetes, Ascomycetes and Hyphomycetes.

35 7.- The method according to any one of claims 1-6, wherein said functionally similar genes are essential genes from Candida Spp, or Aspergillus Spp.

8.- The method according to claim 7, wherein said functionally similar genes are essential genes from *Candida albicans*, or *Aspergillus fumigatus*.

5        9.- The method according to any one of claims 1-8 wherein the functionally similar gene has a sequence identity, at the nucleotide level, with the corresponding essential gene of at least 50%, preferably of at least 60%, and most preferably of at least 70%.

10

10.- The method according to any one of claims 1-8 wherein the functionally similar gene encodes a protein having a sequence identity, at the amino-acid level, with the corresponding essential gene encoded protein of at  
15        least 40%, preferably of at least 50%, more preferably of at least 60% and most preferably of at least 70%.

11.-Gene CaNL256 having the sequence corresponding to SEQ ID NO:2, a functionally similar gene or a functional  
20        fragment thereof.

12.-Gene CaBR102 having the sequence corresponding to SEQ ID NO:4, a functionally similar gene or a functional  
25        fragment thereof.

25

13.-Gene CaIR012 having the sequence corresponding to SEQ ID NO:6, a functionally similar gene or a functional  
30        fragment thereof.

~~14. A gene according to claim 11, 12 or 13, wherein  
the functionally similar gene has a sequence identity, at  
the nucleotide level, of at least 50%, preferably of at  
least 60%, and most preferably of at least 70%.~~

35        15.-A gene according to claim 11, 12 or 13, wherein the functionally similar gene has a sequence identity, at the amino-acid level, with the encoded protein, of at least 40%, preferably of at least 50%, more preferably of at least 60% and most preferably of at least 70%.

16 -A protein encoded by the gene of claim 11, 12 or 13, or a functional polypeptide fragment thereof.

5 17.-A plasmid containing the gene of claim 11, 12 or 13.

18.-A plasmid deposited at the CNCM with the accession number I-2065.

10

19.-A plasmid deposited at the CNCM with the accession number I-2063.

15 20.-A plasmid deposited at the CNCM with the accession number I-2064.

21.- An antibody directed against the protein of claim 16 or a functional polypeptide fragment thereof.

20 22.- A kit for diagnosis of fungal infections comprising a gene selected from the group consisting of CaNL256, CaBR102 and CaIR012, a functionally similar gene thereof, a functional fragment thereof, the corresponding encoded protein or a functional polypeptidic fragment thereof, or an antibody directed against the protein  
25 encoded by the gene selected from the group consisting of CaNL256, CaBR102 and CaIR012, or a polypeptidic fragment thereof.



EPO - DG 1

48

17. 09. 1998

## ABSTRACT:

5 The present invention concerns a method for the screening of antimycotic substances wherein an essential gene from mycetes or a functionally similar mycete gene, or the corresponding encoded protein, is used as target and wherein the essential gene is selected from the group consisting of CaNL256, CaBR102 and CaIR012.

10 The invention also concerns these genes and plasmids containing same.

Fig.3





EPO - DG 1

33

Fig.1  
SEQ ID NO:1

17. 09. 1998

1) Information for SEQ ID NO:1

- 5 (i) sequence characteristics  
A) Length: 399 bp  
B) type: nucleotides  
D) topology: linear  
(ix) Characteristics: probe  
10 (xi) Sequence Description

ATTCATCCCA TCAGTGCAGA AAGTTTGCAT AGCCATTTAC AACAAATTAAT AAATGATAAA 60

CCTCAAGAGA CAGTACAAGA ATCGTCTGAT TTATTACAAT TTATCCCAGT CTCTAGATTA 120

15 CCTGTCAAAG ATAATATTTT GAAATTTGAT CAAATTAATC ATAAATCTCC TACTTTGATT 180

ATGGGTATAT TGAATATGAC TCCTGATTCA TTTAGTGATG GTGGGAAACA TTTTGGAAAA 240

20 GAACTAGATA ATATTGTGAA GCAGGCAGAG AAATTAGTCA GTGAGGGTGC TACGATTATT 300

GACATTGGAG GAGTTTCCAC ACGACCAGGA AGTGTTGAAC CCACTGAGGA AGAAGAATTG 360

25 GAACGTGTGA TTCCATTAAT TAGAGCTATT CGTCAATCA 399

Fig.2

1 .....IHPISAESLHSHLQQQLINDKPQ 22  
5 :||:| | : | | | | . .  
451 PDLNIPHPRLERTFVLEPLCELISPVHLHPVTAEPIVDHLKQLYDKQHD 500  
23 ETV.....QESSDLLQFIPVSRLPVKDNILKFDQINHKSPTLIMGIL 64  
10 | | | | | | | | | | : | : | | | | | | | |  
501 EDTLWKLVPLPYRSGVEPRFLKFKTATKLDEFTGETNRITVSPTYIMAIF 550  
65 NMTPDSFSDGGKHFG...KELDNIVKQA.EKLVSEGATIIDIGGVSTRPG 110  
| | | | | | | | | | : | | | | : | | | | | | | |  
15 551 NATPDSFSDGGEHFADIESQLNDI IKLCKDALYLHESVIIDVGGCSTRPN 600  
111 SVEPTEEEELERVIPLIRAIRQS..... 133  
| : : . | | | : | | | | : | | | : |  
601 SIQASEEEEIRRSIPLIKAIRESTELPQDKVILSIDTYRSNVAKEAIKVG 650

Fig.3  
SEQ ID NO:2

- 1) Information for SEQ ID NO:2
- 5 (i) sequence characteristics
- A) Length: 2367 bp
- B) type: nucleotide
- C) strandedness: single strand
- D) topology: linear
- 10 (ii) molecule type: DNA (genomic)
- (vi) origin: *C. albicans*
- (ix) Characteristics: clone
- (ix) Characteristics: 1-2364: coding sequence
- (ix) Characteristics: exhibit dihydropteroate synthase and
- 15 7,8-dihydro-6-hydroxymethylpterin-pyrophosphokinase activity.
- (ix) Characteristics: gene CanL256
- (xi) Sequence Description

20

1 ATGTTGAAAAACGATACCGTTTTCTACTAAAGATATTTCTTGTACGGCGATAACTGGTAAA  
M L K N D T V F T K D I S C T A I T G K

25

61 GATGCCTGGAATCGGCCAACACCACAACCAATCACTATATCATTATCTTTCAATACTGAT  
D A W N R P T P Q P I T I S L S F N T D

30

121 TTCCATAAGGCATCGGAATTGGATAATTTGAAATACTCAATTAATTATGCTGTTATTACC  
F H K A S E L D N L K Y S I N Y A V I T

35

181 AGAAATGTAAGTGAATTTATGAAATCAAATGAGCATTTAAATTTCAAGTCATTAGGAAAT  
R N V T E F M K S N E H L N F K S L G N

40

241 ATTGCTCAAGCAATTAGTGATATTGGATTAGATCAATCTAGAGGTGGTGGATCTATTGTG  
I A Q A I S D I G L D Q S R G G G S I V

301 GATGTGACGATAAAAAGTTTGAAATCAGAAATAAGAGCTGAAAGTGTGCAATATAAAATT  
D V T I K S L K S E I R A E S V E Y K I

45

361 AATAGAAACACTTTGGGTCAACCCGTTCCATTAGATATTTTCCAAGTTAATAAATTGAGA  
N R N T L G Q P V P L D I F Q V N K L R

50

421 TTATTGACGATTATTGGAGTTTTACATTTGAAAGATTACAAAAACAAATAGTTGATGTT  
L L T I I G V F T F E R L Q K Q I V D V

55

481 GATTTGCAATTTAAATTTGAACCTAATTCCAATTTATATTTCCATCAAATAATTGCTGAT  
D L Q F K I E P N S N L Y F H Q I I A D

541 ATTGTTTCATACGTGGAATCATCTAATTTCAAAACTGTAGAAGCATTGGTGTCTAAGATT

36

I V S Y V E S S N F K T V E A L V S K I

5 601 GGTCAATTGACATTTTCAGAAATATGACGGAGTAGCTGAAGTTGTTGCTACTGTCCTAA  
G Q L T F Q K Y D G V A E V V A T V T K

10 661 CCGAATGCATTTAGTCATGTTGAAGGTGTTGGAGTATCATCTACCATGGTCAAAGACAAT  
P N A F S H V E G V G V S S T M V K D N

15 721 TTCAAAGATATGGAACCAAGTTAAATTTGAAAACACAATTGCTCAAACCTAATAGAGCATTC  
F K D M E P V K F E N T I A Q T N R A F

20 781 AATTTACCTGTTGAAAATGAGAAAACCTGAGGATTATACCGGGTACCACACTGCATTTATT  
N L P V E N E K T E D Y T G Y H T A F I

25 841 GCCTTTGGATCCAATACTGGAAATCAAGTAGAAAATATTACCAATTCATTCTGAATTGTTG  
A F G S N T G N Q V E N I T N S F E L L

30 901 CAAAAATATGGAATCACCATAGAAGCAACTTCATCATTGTACATTTCTAAACCAATGTAT  
Q K Y G I T I E A T S S L Y I S K P M Y

35 961 TACTTGGATCAACCAGATTTTTTCAATGGAGTAATTAAAGTGAATTTCCAAACATTTCA  
Y L D Q P D F F N G V I K V N F Q N I S

40 1021 CCTTTCAGTTGTTGAAAATTCTAAAAGATATTGAATATAAACATTTAGAAAGGAAAAAA  
P F Q L L K I L K D I E Y K H L E R K K

45 1081 GACTTTGATAATGGGCCCAGATCAATAGATTGATATTATACTATATGACGATTACAA  
D F D N G P R S I D L D I I L Y D D L Q

50 1141 TTAAATACCGAGAATCTAATTATTCCACATAAATCAATGTTAGAAAGAACATTTGTATTA  
L N T E N L I I P H K S M L E R T F V L

55 1201 CAACCATTATGTGAAGTATTGCCCCCTGATTATATTCATCCCATCAGTGCAGAAAGTTTG  
Q P L C E V L P P D Y I H P I S A E S L

1261 CATAGCCATTTACAACAATTAATAAATGATAAACCTCAAGAGACAGTACAAGAATCGTCT  
H S H L Q Q L I N D K P Q E T V Q E S S

1321 GATTTATTACAATTTATCCCAGTCTCTAGATTGCCTGTCAAAGATAATATTTTGAAATTT  
D L L Q F I P V S R L P V K D N I L K F

1381 GATCAAATTAATCATAAATCTCCTACTTTGATTATGGGTATATTGAATATGACTCCTGAT  
D Q I N H K S P T L I M G I L N M T P D

37

1441 TCATTTAGTGATGGTGGGAAACATTTTGGAAAAGAACTAGATAATACTGTGAAGCAGGCA  
S F S D G G K H F G K E L D N T V K Q A

5

1501 GAGAAATTAGTCAGTGAGGGTGCTACGATTATTGACATTGGAGGAGTTTCCACACGCCCA  
E K L V S E G A T I I D I G G V S T R P

10

1561 GGAAGTGTTGAACCCACTGAGGAAGAAGAATTGGAACGTGTGATTCCATTAATTAAGCT  
G S V E P T E E E E L E R V I P L I K A

15

1621 ATTCGTCAATCACTGAACCCTGATTACTGAAGGTGTTGATTTCGGTTGATACTTATCGT  
I R Q S L N P D L L K V L I S V D T Y R

20

1681 AGGAACGTTGCTGAACAAAGTTTACTTGTGGGTGCTGACATAATCAACGATATCTCAATG  
R N V A E Q S L L V G A D I I N D I S M

25

1741 GGCAAATATGATGAAAAAATATTTGATGTGGTTGCTAAATACGGATGTCCTTATATCATG  
G K Y D E K I F D V V A K Y G C P Y I M

30

1801 AATCATACTCGAGGATCACCTAAAACCATGTCTAAATTGACCAATTATGAATCAAATACA  
N H T R G S P K T M S K L T N Y E S N T

35

1861 AATGATGATATTATCGAATATATAATTGATCCTAAATTAGGACATCAAGAATTGGATTG  
N D D I I E Y I I D P K L G H Q E L D L

40

1921 TCACCTGAAATCAAGAATTTACTCAATGGAATCAGTCGTGAATTGAGTTTACAAATGTTT  
S P E I K N L L N G I S R E L S L Q M F

45

1981 AAAGCCATGGCTAAAGGAGTGAAAAAATGGCAAATTATTTTGGATCCTGGTATTGGATTT  
K A M A K G V K K W Q I I L D P G I G F

50

2041 GCTAAAAATTTGAATCAAAATTTAGCAGTTATTCGTAATGCCTCGTTTTTTAAAAAATAT  
A K N L N Q N L A V I R N A S F F K K Y

55

2101 TCTATTCAAATTAATGAACGTGTTGATGATGTGACAATCAAACATAAATATTTAAGTTTT  
S I Q I N E R V D D V T I K H K Y L S F

2161 AATGGTGCTTGTGTTTTGGTGGGGACATCAAGAAAGAAGTTTTTGGGGACATTAAGTGGT  
N G A C V L V G T S R K K F L G T L T G

2221 AATGAAGTGCCTCTGGATCGAGTATTTGGCACTGGTGCAACAGTGTCTGCGTGTATTGAA  
N E V P L D R V F G T G A T V S A C I E

2281 CAAAACACTGATATTGTAAGAGTTCATGATGTTAAAGAAATGAAAGATGTAGTATGTAT

11-09-1998

EP98402255.8

DRAW

38

Q N T D I V R V H D V K E M K D V V C I

5      2341    AGTGATGCAATTTATAAAAATGTATAA    2367  
         S D A I Y K N V \*

Printed:03-11-1999

DNEDOCID: JE1 0040225502

Fig.4,  
SEQ ID NO:3

- 5 1) Information for SEQ ID NO:3  
(i) sequence characteristics  
A) Length: 647 bp  
B) type: nucleotides  
D) topology: linear  
10 (ix) Characteristics: probe  
(xi) Sequence Description

15 AGTATTCAAT TGGGTATTCC CAGTAATAAA AAGAAAGATC GATCATCAAT TATGGTGCTT 60  
AAAAAAATGT GGGATTCTCA ATTACAATCA TTATTTAAAC ATGTTGACGG TGCATCAAAA 120  
TTTGTGCAAC CATTACCCAA TAGACACATT GTCGCGGAAA GTGGACGATG GTTTGAAGTT 180  
20 AATGTGGGGA ATTGGAAACC AAGTTATCCA ACTCATTTAT TTATATTTAA TGATTTAATT 240  
TTAATTGCCG TTAAAAAATC ATCATCTAGT AGTCAGGAAC CTACTACAGG GGAAGTAAT 300  
GGTGGTTCAA AATCGAGATT ACAAGCGGTT CAATGTTGGC CCTTAACTCA AGTATCATT 360  
25 CAACAAATCA AATCACCGAA AAAAGATGAC GATAAGATGT ATTTTATCAA TCTTAAATCC 420  
AAATCTTTAA GTTATGTATA CCTGACGGAT CGTTATGATC ATTTTGTGAA AGTTACGGAA 480  
30 GCATTTAATA AAGGTAGAAA TGAAATGATT CAAAGTGAAA GATTATTAGA TTCAAGACTT 540  
TCATCTCCTT CAAATAATAA TGGAGATTCT AAAGAAGAGA AACGACAATT ACGGGAATCA 600  
TTAAGAAACT CAGGCAATTA TAAAGAAGGA GTTACTGATG ATGCCGG 647  
35

Fig.5

5 251 NDLNEVLDQCTKIAEKRLQLQDQIDQERQGNFNNVESHSNSPALLPPLKA 300  
1 ..... KSIQL 5  
10 301 GQNGNLMRRDRSSVLILEKFWDTELDQLFKNVEGAQKFINSTKGRHILMN 350  
6 GIPSN.KKKDRSSIMVLKKMWDSQLQSLFKHVDGASKFVQPLPNRHIVAE 54  
351 SANWMELNNTTGGKPLQMVQIFILNDLVLIADK...SRDKQNDFIVSQCY 397  
15 55 SGRWFEVNVGNWKPSYPHTLFI FNDLILIAVKKSSSSSQEPTTGGSNGGS 104  
398 LKDVTVTQEEFSTKRLLFKFSNSNSSLYECRDADECSRLLDVI..RKAKD 445  
105 KSRLQAVQCWPLTQVSLQQIKSPKDDDKMYFINLKSKSLSYVYLTDRYD 154  
20 446 DLCDIFHVEEENSKRIRESFRYLQSTQQTGRENNRSPNKNK..RRSMGG 493  
155 HFVKVTEAFNKG RNEMIQSERLLDSRLSSPSNNGDSKEEKRLRESLRN 204  
25 494 SITPGRNVTGAMDQYLLQNLTLMSHSRPRSRDMSSTAQRLKFLDEGV EEI 543  
205 SGNYKEGVTTDDAGGAATG\*VT..... 225



41

FIG.6

SEQ ID NO:4

- 1) Information for SEQ ID NO:4
- 5 (i) sequence characteristics
- A) Length: 2373 bp
- B) type: nucleotide
- C) strandedness: single strand
- D) topology: linear
- 10 (ii) molecule type: DNA (genomic)
- (vi) origin: *C. albicans*
- (ix) Characteristics: clone
- (ix) Characteristics: 1-2373: coding sequence
- (ix) Characteristics: gene CaBR102.
- 15 (xi) Sequence Description

```

20      1  ATGGATAATCTTGATCCCAATTCTAGTTTACAAGTAGAGAAATTACGAAA  50
      1  M D N L D P N S S L Q V E K L R N  17

      51  CAGGAAAAGCAGGGCTGTATGGCAGAATAACAACACTTCTACTCATAATA  100
      18  R K S R A V W Q N N N T S T H N N  34

25      101  ATCCTTATGCTAATTTAAGCACTGGTGAAAAAAGTAGGAGTCGCCATAAC  150
      35  P Y A N L S T G E K S R S R H N  50

      151  ACTGGTAGTTCTTATGTTTCTCCATATGGCGGCGGTAATGGAGAGGAGAA  200
      51  T G S S Y V S P Y G G G N G E E N  67

30      201  TGCTTATACTGGGAATAACAACAAATCAAATACTAGTGGTAATTTATTAC  250
      68  A Y T G N N N K S N T S G N L L Q  84

      251  AAGTTCCTGGAGCAGGAGGAGGAGGAGATTTGAATTCTAATAAGAAACAA  300
40      85  V P G A G G G G D L N S N K K Q  100

      301  AGTCGAAGAATGAGTATTCATGTATCAGCTCGTCAACATGGAAGATCATT  350
      101  S R R M S I H V S A R O H G R S F  117

45      351  TTCACAAACTGGTCCAATTGATATGGCAAATTTACCGGCATTACCTAAAA  400
      118  S Q T G P I D M A N L P A L P K I  134

      401  TAGGTGGTGTTACTACTAGTGGTGTTGGCGGTGCTGGTGGTGATGTTATG  450
50      135  G G V T T S G V G G A G G D V M  150

      451  ACAAGGACTGGGGGATTGACGATAGAACAAAAATATTCAAAGAATTAAG  500
55      151  T R T G G L T I E Q K I F K E L S  167

```

42

	501	TCAAGGATCAGCAGCTGAAGTTGATGATTATTACAAGACATTATTGAAAC	550
	168	Q G S A A E V D D Y Y K T L L K Q	184
5	551	AGAAAAATTTAATCACTCGTGACATTAAGGATAATATTAATCAGAATCAA	600
	185	K N L I T R D I K D N I N Q N Q	200
10	601	AAAAATATTTTACAATTAACAAAAGACTTGAAAGAGACCCAAGAAGAATT	650
	201	K N I L Q L T K D L K E T Q E E L	217
15	651	GATTGAATTGAGAGGAACCACTAAAGAATTATATGAAGTTTTAGGTTATT	700
	218	I E L R G T T K E L Y E V L G Y F	234
20	701	TCAAAGAATCAGCTCAACGTAGATTAGAATTGGAATTTGAACCAGAAACA	750
	235	K E S A Q R R L E L E F E P E T	250
25	751	CAAAAAGAACTTCATCTGCCTCAAAAAGTAATCAATTGGGTATTCCTAG	800
	251	Q K E L H L P Q K S N Q L G I P S	267
30	801	TAATAAAAAGAAAGATCGATCATCAATTATGGTGCTTAAAAAATGTGGG	850
	268	N K K K D R S S I M V L K K M W D	284
35	851	ATTCTCAATTACAATCATTATTTAAACATGTTGACGGTGCATCAAAATTT	900
	285	S Q L Q S L F K H V D G A S K F	300
40	901	GTCCAACCATTAACCAATAGACACATTGTCGCGGAAAGTGGACGATGGTT	950
	301	V Q P L P N R H I V A E S G R W F	317
	951	TGAAGTTAATGTGGGGAATTGGAAACCAAGTTATCCAATCATTATTTA	1000
	318	E V N V G N W K P S Y P T H L F I	334
	1001	TATTTAATGATTTAATTTTAATTACTGTTAAAAAATCATCATCTAGTAGT	1050
	335	F N D L I L I T V K K S S S S S	350
45	1051	CAGGAACCTACTACAGGGGGAAGTAATGGTGGTTCAAAATCGAGATTACA	1100
	351	Q E P T T G G S N G G S K S R L Q	367
50	1101	AGCGGTTCAATGTTGGCCCTTAACTCAAGTATCATTACAACAAATCAAAT	1150
	368	A V Q C W P L T Q V S L Q Q I K S	384
55	1151	CACCGAAAAAGATGACGATAAGATGTATTTTATCAATCTTAAATCCAAA	1200
	385	P K K D D D K M Y F I N L K S K	400
	1201	TCTTTAAGTTATGTATACCTGACGGATCGTTATGATCATTTTGTGAAAGT	1250
	401	S L S Y V Y L T D R Y D H F V K V	417

43

5

1251 TACGGAAGCATTTAATAAAGGTAGAAATGAAATGATTCAAAGTGAAAGAT 1300  
418 T E A F N K G R N E M I Q S E R L 434

10

1301 TATTAGATTCAAGACTTTCATCTCCTTCAAATAATAATGGAGATTCTAAA 1350  
435 L D S R L S S P S N N N G D S K 450

15

1351 GAAGAGAAACGACAATTACGGGAATCATTAAGAAACTCAGGCAATTATAA 1400  
451 E E K R Q L R E S L R N S G N Y K 467

20

1401 AGAAGGAGTTACTGATGATGCCGGTGGAGCTGCAACTGGTGGTGGTAGGA 1450  
468 E G V T D D A G G A A T G G G R K 484

25

1451 AAAGTGCCGGTACTCCTAATAGAAATAGTACTGATTACGTTTTACATGAT 1500  
485 S A G T P N R N S T D Y V L H D 500

30

1501 ATATCTGCTCGAGTACATTACGTAATCGATCACAAGATTAGGGAATAA 1550  
501 I S A R V H S R N R S Q D L G N N 517

35

1551 TTTCAAATTAGCTAATAATGGGAAATCACAATTTTTCAATGAAATCAAAA 1600  
518 F K L A N N G K S Q F F N E I K T 534

40

1601 CTTTAGAAGATCGATTAGATGATGTTGACGTTGAAATATCGCATAATCAA 1650  
535 L E D R L D D V D V E I S H N Q 550

1651 TATGCTGAAGCCGTGGAATTAATATCAATAATTGAATCTAAATTACGTAA 1700  
551 Y A E A V E L I S I I E S K L R N 567

1701 TATTGAAAATGCATTAATAATCAACGTAATGGAGGTAAAAATGTCAATA 1750  
568 I E N A L T N Q R N G G K N V N I 584

1751 TTGCTGATGAATTATTACTTTTAGATGTATCAAAATTGAAAATTAAAAAT 1800  
585 A D E L L L L L D V S K L K I K N 600

45

1801 CGGAAAGAAAATGTATCTAATGGATTAATATTTGATTACACATAATAT 1850  
601 R K E N V S N G L I F D L Q H N I 617

50

1851 AGCTAAACTTAAACAAGATGATATTGATAATATTTTGACGTTATTTGATA 1900  
618 A K L K Q D D I D N I L T L F D N 634

55

1901 ATTTAGAGCAATTAGATCGAGGGGTTCAAGGATATTTGGATTCAATGTCA 1950  
635 L E Q L D R G V Q G Y L D S M S 650

44

	1951	GCTTATTTATCAACTACAGTATCAAAATTAATTGTTGGTTTACAAGGATC	2000
	651	A Y L S T T V S K L I V G L Q G S	667
5	2001	AACGAAAATCGATGTTGTTAATTATCTTTCCAATTTAATGGTTATTAATG	2050
	668	T K I D V V N Y L S N L M V I N V	684
10	2051	TATCGATTGTGAAACGTACAATTCAAACCTTATGAACAAATAATTGCTCCA	2100
	685	S I V K R T I Q T Y E Q I I A P	700
15	2101	ATTTTAAAACGTCATGGTGATGTTGATTCAAGTGGATTGATTAATTGGTG	2150
	701	I L K R H G D V D S S G L I N W C	717
	2151	TATTGATGAATTTACTAAACTTTGTAAACAAATTAAAAAACATTTGTATG	2200
	718	I D E F T K L C K Q I K K H L Y G	734
20	2201	GAACATTGTTGATATCTTCTGGGATTAATATGGAAACTGATGAACCAATT	2250
	735	T L L I S S G I N M E T D E P I	750
25	2251	TATAAAGTTAAAGAAAGAAAATTATATGATAATTTCTTGAAGATTATGCA	2300
	751	Y K V K E R K L Y D N F L K I M Q	767
30	2301	ACCACAATTGGAAGAATTAAAACCTGGTGGGATTAATGTTGATTATATAT	2350
	768	P Q L E E L K L V G L N V D Y I F	784
35	2351	TTGAGTCTATATTAAATCTTGAA	2373
	785	E S I L N L E	791

45

Fig.7,  
SEQ ID NO:5

- 1) Information for SEQ ID NO:5  
5 (i) sequence characteristics  
A) Length: 343 bp  
B) type: nucleotides  
D) topology: linear  
(ix) Characteristics: probe  
10 (xi) Sequence Description

CTGCAGTAAA CCCTCCAGAT ATAACAGACT CTTTATGTCC AGTGATTTCG CCAACAAATC 60  
15 TTGGTGTTG GGTGTGTGTG GTCCATAAGT ATGCCGTGTT GTCACCACCC CCAGTCAATA 120  
CCATTGGCAA TTTAGGATGT GAAAAAATAG TAAATATACT ATCGGTATGT TTATCAAAT 180  
AAGTCCATGA ATTGTTGGAC ATGTCAATTT CTAAAGTCTC ATGCTCATCA TCTAATTCCA 240  
20 TCTCCTCATC TTCTTCATCG GGTGGCGCTT GATCATCATC TGCAACTTCC TCAGCCACTT 300  
CATTAACATT GATATATTCT TCTTGAGTAT CGTCTACGAC GTC 343  
25

FIG.8

SEQ ID NO:6, CaIR012.

- 1) Information for SEQ ID NO:2  
5 (i) sequence characteristics  
A) Length: 1248 bp  
B) type: nucleotide  
C) strandedness: single strand  
D) topology: linear  
10 (ii) molecule type: DNA (genomic)  
(vi) origin: *C. albicans*  
(ix) Characteristics: clone  
(ix) Characteristics: 1-1245: coding sequence  
(ix) Characteristics: gene CaIR012.  
15 (xi) Sequence Description

ATGTCACACCAACAAGAAGACGTCGTAGACGATACTCAAGAAGAATATATCAATGTTAAT 60  
M S H Q Q E D V V D D T Q E E Y I N V N  
20 GAAGTGGCTGAGGAAGTTGCAGATGATGATCAAGCGCCACCCGATGAAGAAGATGAGGAG 120  
E V A E E V A D D D Q A P P D E E D E E  
ATGGAATTAGATGATGAGCATGAGACTTTAGAAATTGACATGTCCAACAATTCATGGACT 180  
25 M E L D D E H E T L E I D M S N N S W T  
TATTTTGATAAACATACCGATAGTATATTTACTATTTTTTTCACATCCTAAATTGCCAATG 240  
Y F D K H T D S I F T I F S H P K L P M  
GTATTGACTGGGGGTGGTGACAACACGGCATACTTATGGACCACACACACCCCAACCACCA 300  
30 V L T G G G D N T A Y L W T T H T Q P P  
AGATTTGTTGGCGAAATCACTGGACATAAAGAGTCTGTTATATCTGGAGGGTTTACTGCA 360  
35 R F V G E I T G H K E S V I S G G F T A  
GACGGCAAGTTTGTGTGTTACTGCAGACATGAATGGATTAATTCAAGTTTCAAAGCCACA 420  
D G K F V V T A D M N G L I Q V F K A T  
AAAGGAGGTGAACAGTGGGTGAAATTTGGTGAATTGGACGAAGTTGAAGAAGTGTGTGTT 480  
40 K G G E Q W V K F G E L D E V E E V L F  
GTTACTGTGCATCCAACATTACCATTCTTTGCCTTTGGTGCTACCGATGGATCTATATGG 540  
V T V H P T L P F F A F G A T D G S I W  
GTCTACCAAATAGACGAATCCAGTAACTGCTAGTGCAAATTATGTCTGGGTTCTCACAC 600  
V Y Q I D E S S K L L V Q I M S G F S H  
ACATTAGAATGTAATGGTGTCTGTTTATACAAGGAAAAGATGAAAATGATTTGACATTG 660  
50 T L E C N G A V F I Q G K D E N D L T L  
GTCTCTATAAGTGAAGATGGTACTGTGGTGAAGTGGAACTGTTTTACAGGACAAGTGAAT 720  
V S I S E D G T V V N W N C F T G Q V N  
TATAAATTGCAACCTCATGATGACTTTAAAGGAGTTGAAAGTCCGTGGGTACGGTCAAA 780  
55 Y K L Q P H D D F K G V E S P W V T V K  
GtACATGGTAATCTTGTGGCCATTGGTGGCAGAGATGGCCAGCTATCAATTGTGAACAAT 840  
V H G N L V A I G G R D G Q L S I V N N

47

GACACTGGTAAAAATCGTTCATACTCTTAAACATTGGATAATGTCGACGACATTGCAGAA 900  
D T G K I V H T L K T L D N V D D I A E

5 CTCTCAATTGAGGCATTGAGTTGGTGTGAAAGCAAAAATATTAACCTCTTGGCAGTGGGT 960  
L S I E A L S W C E S K N I N L L A V G

TTGGTTTCTGGTGACGTTTTATTATTTGATACTCAGCAATGGAGATTGAGAAAGAAGTTG 1020  
L V S G D V L L F D T Q Q W R L R K N L

10 AAAGTTGACGATGCCATCACCAAATTACAATTTGTTGGCGAAACCCCATTTTGGTGGGA 1080  
K V D D A I T K L Q F V G E T P I L V G

AGTAGTATGGATGGTAAAATTTACAAATGGGACGCTAGAACTGGTGAAGAGTTGTTTGCT 1140  
15 S S M D G K I Y K W D A R T G E E L F A

GGTGTGGGACACAACATGGGAGTATTGGACTTTGCTATTTTAGATGGAGGTAAAAAGTTG 1200  
G V G H N M G V L D F A I L D G G K K L

20 GTTACTGCTGGTGATGAAGGTGTTTCATTGGTCTTTGTACATGAATAG 1248  
V T A G D E G V S L V F V H E .

**THIS PAGE BLANK (USPTO)**